Destiny Pharma invited to present at the inaugural Pipeline Corner event to be held during the 25th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) meeting in Copenhagen, Denmark on the 25-28th April 2015

Destiny Pharma has been invited to present at the at the inaugural Pipeline Corner @ ECCMID event to be held during the 25th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) meeting in Copenhagen, Denmark on the 25-28th April 2015. Please contact us on info@destinypharma.com if you would like to arrange a meeting during this year’s ECCMID meeting.

05 Feb 2015 – Global Innovation Fund recommended to be set up to support new ideas to combat antimicrobial resistance

Following on from the report produced in December 2014 by the Review on Antimicrobial Resistance, set up by the UK Prime Minister David Cameron, where it was estimated that drug-resistant infections will cost the world 10 million extra deaths a year and up to $100 trillion by 2050, the Review on Antimicrobial Resistance has today issued it’s latest report where it recommends that a global antimicrobial resistance innovation fund should be set up to drive investment in R&D focused on a new generation of drugs to tackle the issue of antimicrobial resistance. Jim O’Neill, Chairman of the Review on Antimicrobial Resistance, said: “I am calling on international funders, philanthropic or governmental, to allocate money to a fund that can support blue sky science and incubate ideas that are more mature. Antibiotics research is the poor relation to studying chronic diseases of the developed world but, without antibiotics, treating those diseases can be compromised too. New drugs take 10 to 15 years to come onto market, so the time for action is now“. The Review on Antimicrobial Resistance team will publish their next report in the spring of 2015, which will focus on incentives to create a compelling commercial rationale for developing new drugs to tackle antimicrobial resistance. Changes that governments, health provides and health regulators will need to bring about to achieve this aim will be identified. Dr Bill Love, CEO of Destiny Pharma said: “I welcome the Review on Antimicrobial Resistance’s latest report and their identification for the need to set up an innovation fund and look forward to their recommendations on how the commercial landscape can be improved to incentivise further investment to combat antimicrobial resistance“.

08 Jan 2015 – Destiny Pharma to attend DRIVE-AB (Driving reinvestment in R&D and the responsible use of antibiotics) meeting in London on February 9th

Destiny Pharma has been invited to attend the DRIVE-AB (Driving reinvestment in R&D and the responsible use of antibiotics) meeting to be held at the Royal Automobile Club in London on the February 9th 2015. DRIVE-AB is a project composed of 16 public and 7 private partners from 12 countries that is funded by the Innovative Medicines Initiative (IMI): IMI is a joint undertaking between the European Union and the European Pharmaceutical Industry Association (EFPIA) and is focused on driving reinvestment in R&D for antibiotics and advocating their responsible use.

19 Dec 2014 – Drug-resistant superbugs could cost up to $100 trillion and cause 10 million extra deaths a year by 2050

In a report published on the 11th December by the Review on Antimicrobial Resistance, set up by the UK Prime Minister David Cameron, it has been estimated that drug-resistant infections will cost the world 10 million extra deaths a year and up to $100 trillion by 2050, if the global increase is not stopped. Drug-resistant infections already kill hundreds of thousands of people globally every year, and the trend is growing. The analysis was produced by RAND and KPMG, with input from experts in the scientific community. Jim O’Neill, Chairman of the Review on AMR, said: “Drug-resistant infections already kill hundreds of thousands a year globally, and by 2050 that figure could be more than 10 million. The economic cost will also be significant, with the world economy being hit by up to $100 trillion by 2050 if we do not take action.” Dr Bill Love, CEO of Destiny Pharma said “The figures in this report, particularly the potential human cost of not addressing antibiotic resistance are quite frightening. Fortunately the report does make the case that this crisis can be averted if global action is taken soon to address this huge problem the report highlights just how great the need for new antimicrobial drugs is.”

05 Dec 2014 – Destiny Pharma invited to attend the first event of the Review on Antimicrobial Resistance Meeting chaired by Jim O’Neill and hosted by the Wellcome Trust on the 11th December 2014

Destiny Pharma have been invited to attend the first event for the Review on Antimicrobial Resistance which has been set up by David Cameron, the British Prime Minister to be held at the Wellcome Trust in London. Jim O’Neill, the chairman of the review, will present a paper looking at how much antimicrobial resistance could cost the world by 2050 if it is not tackled. The meeting will also discuss two questions with expert speakers, followed by an interactive discussion:

1. What will it take for new diagnostic technology to become reality? What policy changes are needed to change prescription practices and revolutionise the surveillance of diseases?

2. New antimicrobial drugs: How empty is the pipeline? Is the problem science or money?

17 Nov 2014 – Antibiotic Awareness Day

European Antibiotic Awareness Day is marked annually on the 18th November to raise awareness about the threat to public health of antibiotic resistance and prudent antibiotic use. The latest data confirms that across the European Union the number of patients infected by resistant bacteria is increasing and that antibiotic resistance is a major threat to public health. On the occasion of the 7th European Antibiotic Awareness Day, the European Centre for Disease Prevention and Control (ECDC) will be releasing its latest EU-wide data on antibiotic resistance (EARS-Net annual report and interactive database). The ECDC data will show that the rate at which the percentage of Staphylococcus aureus resistant to methicillin (MRSA) decreased for the period 2010 to 2013 was reduced compared to the previous four-year period, despite all of the initiatives in place to fight this superbug. MRSA remains a major public health problem in Europe, with seven out of thirty reporting countries having MRSA percentages above 25%. The European Antibiotic Awareness Day is part of the UK 5 Year Antimicrobial Resistance Strategy 2013 to 2018, which focuses on antibiotics and sets out actions to slow the development and spread of antimicrobial resistance. This year, Public Health England has established the Antibiotic Guardian pledge campaign. More information about the 7th European Antibiotic Awareness Day can be found here, here and here.

01 Oct 2014 – Destiny Pharma to attend IDWeek in Philadelphia, PA

Destiny Pharma will be attending IDWeek in Philadelphia, PA between 8-12th October. IDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA) the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). IDWeek is geared toward healthcare professionals in infectious diseases and healthcare epidemiology and prevention, including researchers, clinicians, quality and patient safety practitioners, epidemiologists, and public health officials. Please contact us on info@destinypharma.com if you would like to arrange a meeting during IDWeek.

29 Sep 2014 – Obama Administration Takes Actions to Combat Antibiotic-Resistant Bacteria

On the 18th September, President Barack Obama signed an Executive Order directing key Federal departments and agencies to take action to combat the rise of antibiotic-resistant bacteria. The Administration also released its National Strategy on Combating Antibiotic-Resistant Bacteria. In addition, the President’s Council of Advisors on Science and Technology (PCAST) has released a related report on Combating Antibiotic Resistance. The Executive Order directs Federal departments and agencies to implement the National Strategy and address the PCAST report. The National Strategy provides a five-year plan for enhancing domestic and international capacity to: prevent and contain outbreaks of antibiotic-resistant infections; maintain the efficacy of current and new antibiotics; and develop and deploy next-generation diagnostics, antibiotics, vaccines, and other therapeutics. The PCAST report provides actionable recommendations from the President’s Council, in consultation with experts from the public and private sectors, for combating antibiotic resistance.

According to the Centers for Disease Control and Prevention (CDC), antibiotic-resistant infections are associated with 23,000 deaths and 2 million illnesses in the United States each year. Estimates of annual impact of antibiotic-resistant infections on the U.S. economy vary but have ranged as high as $20 billion in excess direct health care costs, and as much as $35 billion in lost productivity from hospitalizations and sick days. And the problem is worsening. Some bacterial infections are almost, or entirely, untreatable because the causal agents have acquired resistance to all of the antibiotics that can be deployed against them. Without effective antibiotics, we will no longer be able to treat bacterial infections reliably and rapidly. Antibiotics are critically important for many modern medical interventions, including chemotherapy, complex surgery, and organ transplantation. Controlling the development and spread of antibiotic resistance is a top national security and public health priority for the Obama Administration. Taken together, the Executive Order, National Strategy, and PCAST report will significantly help the Federal government curb the rise of antibiotic-resistant bacteria, potentially saving thousands of lives.

04 Sep 14 – Destiny Pharma to attend 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Conference in Washington DC

Destiny Pharma will be attending the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Washington DC between 5 – 9th September. ICAAC is the premier conference on antimicrobial agents and infectious diseases, showcases the latest-breaking science and lectures from top researchers from around the world. With 50% of its attendees living outside of the United States, ICAAC provides a rare opportunity to bring together the field’s foremost leaders to discuss the state of infection control and prevention on a global scale. Please contact us on info@destinypharma.com if you would like to arrange a meeting during ICAAC.

04 Aug 2014 – Angel CoFund join UK investors in £2.8m investment for Superbug Killing Company

Innovative UK pharmaceutical company, Destiny Pharma, completes investment round to fund a landmark clinical trial of a new drug designed to combat antibiotic resistant bacteria

4th August 2014, Brighton: UK Clinical stage pharmaceutical company, Destiny Pharma, can today announce its successful investment round of over £2.8 million to fund a landmark clinical trial for its lead drug, XF-73, to prevent post-surgical Staphylococcal infections. The Angel CoFund, (the £100m fund for small and medium sized British businesses, with Government backing), invested in Destiny Pharma, alongside other UK investors.

Infection from bacteria remains a worrying complication for hospital admissions. One of the most common causes of infection is the bacterium Staphylococcus aureus (SA). XF-73 is a ‘nasal decolonisation’ treatment intended to clear SA bacteria from the nostrils of carriers, to prevent post-surgical SA infection. It has been proven to be an effective drug for killing both SA and the drug-resistant form of the bacteria, MRSA.

Antibiotic resistance is of growing concern with David Cameron warning that we may be heading into a post-antibiotic era akin to the ‘medical dark ages’. In July this year, he announced an independent review on the subject with a view to make recommendations as to how to stimulate the development of new antibiotics, which will be presented to the G7. Public awareness and support is behind this drive for new antibiotics, demonstrated by Antibiotic Resistance winning the public vote for the £10m Longitude Prize.

The US government is currently funding an on-going clinical trial of XF-73, which further highlights the global interest in Destiny Pharma and its approach to ensure the drug is adopted across all major markets. In July 2014, the US Infective Disease Society of America published new recommendations for the prevention of SA/MRSA infection, which will now include a highest-grade recommendation for nasal decolonisation of all Intensive Care Unit patients to reduce infection.

Dr Bill Love, CEO of Destiny Pharma commented: “We are delighted to have completed this investment and welcome the Angel CoFund along with other new investors. XF-73 has the potential to become a mainstream treatment for the prevention of SA/MRSA hospital infections and its unique feature of addressing antibiotic resistance can enable the widespread delivery of global patient decolonisation. We look forward to the next stages of developing this drug and to enabling its use in hospitals.”

Tim Mills, Investment Director at the Angel CoFund, commented: “Destiny Pharma is exactly the type of business we look to invest in; it is innovative, British and cutting edge in the medical field. This round of investment is for Destiny Pharma’s new drug that will kill bacteria via a novel ultra-rapid kill action – designed to even combat antibiotic resistance. We are looking forward to working with the team and supporting them as the company grows.”

ENDS

About Destiny Pharma:

Destiny Pharma, a clinical stage pharmaceutical company, was founded in 1997. The Company focuses on the R&D of new antimicrobial drugs, with an emphasis on novel mechanisms of action, which seek to address antibiotic resistance. Through its extensive business network and strategic partnerships Destiny Pharma intends to globally commercialise candidates from the XF Drug platform, which are differentiated by design from traditional antibiotics.

AboutAngel CoFund:

Launched in 2011, the Angel CoFund is a privately run fund that works alongside groups of business angels to invest in high growth small and medium sized businesses across the UK, directly providing funding as well as encouraging the expansion of the business angel market.

Backed by the British Business Bank and the Government’s Regional Growth Fund, the £100m Angel CoFund is able to make initial investments of between £100,000 and £1 million into businesses, alongside syndicates of business angels.

To date the fund has supported 42 companies (for example Ventive, Yplan, PlayJam and Micrima) providing over £17 million in direct investment alongside £65 million from business angels and other investors.

www.angelcofund.co.uk

Forward Looking Statement:

This press release contains forward-looking statements that are subject to risks and uncertainties and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Destiny Pharma disclaims any intent or obligation to update forward-looking statements except as required by law.

For further information about Destiny Pharma contact:
Email: pressoffice@destinypharma.com
Tel: +44 (0) 1273 704440

For further information about Angel CoFund contact:
Email: emma@fieldhouseassociates.com
Tel: +44 (0) 7988 696059